Comparison of preliminary results of involved-field with extended field radiotherapy combined with chemotherapy for early stage Hodgkin's disease.
- Author:
Wei-hu WANG
1
;
Ye-xiong LI
;
Yong-wen SONG
;
Jing JIN
;
Yue-ping LIU
;
Shu-lian WANG
;
Li-qiang ZHOU
;
Xin-fan LIU
;
Zi-hao YU
;
Jia-zhu HAN
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; administration & dosage; therapeutic use; Bleomycin; administration & dosage; Combined Modality Therapy; Dacarbazine; administration & dosage; Doxorubicin; administration & dosage; Female; Follow-Up Studies; Hodgkin Disease; drug therapy; pathology; radiotherapy; Humans; Leukopenia; etiology; Lymphatic Irradiation; adverse effects; methods; Lymphatic Metastasis; Male; Mechlorethamine; administration & dosage; Middle Aged; Neoplasm Staging; Prednisone; administration & dosage; Procarbazine; administration & dosage; Recurrence; Retrospective Studies; Survival Rate; Vinblastine; administration & dosage; Vincristine; administration & dosage
- From: Chinese Journal of Oncology 2006;28(3):218-221
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate whether involved-field (IF) radiotherapy is equally effective and less toxic in comparison with extended-field (EF) radiotherapy for patients with early-stage Hodgkin's disease (HD) who received combined modality therapy.
METHODSThe data of 88 early-stage HD patients treated with combined modality therapy were retrospectively reviewed. According to Ann Arbor classification, 12 patients (13.7%) had stage IA disease, 56 stage IIA (63.6%), and 20 IIB (22.7%). Forty-two (47.7%) patients underwent involved field radiotherapy (IF group), whereas the other 46 (52.3%) received extended field radiotherapy (EF group).
RESULTSOf 6 patients who developed recurrence, 3 (7.1%) were in IF group and the other 3 (6.5%) in EF group. Only one patient's recurrence developed inside the radiation field in EF group. Three patients (7.2%) in IF group and 9 (19.5%) in EF group had WHO grade 1 and 2 leukopenia (P = 0.089). Overall survival rate at 1-, 2- and 3-year was 100.0%, 97.1%, and 97.1% in IF group versus 100.0%, 100%, and 95.8% in EF group (P = 0.86), respectively. Freedom from progression survival rate at 1-, 2- and 3-year was 97.6%, 94.8%, and 91.7% in IF group versus 97.8%, 93.2%, and 93.2% in EF group (P = 0.65), respectively.
CONCLUSIONCompared with extended-field radiotherapy, involved-field radiotherapy is equally effective and less toxic for patient with early-stage Hodgkin's disease treated with combined modality therapy.
